Dose-associated pulmonary complication rates after fresh frozen plasma administration for warfarin reversal

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 2, 2016, Pages 324-330

  Marshall, A L ^a   Levine, M ^b   Howell, M L ^c   Chang, Y ^c   Riklin, E ^c   Parry, B A ^c   Callahan, R T ^c   Okechukwu, I ^c   Ayres, A M ^c   Nahed, B V ^c   Goldstein, J N ^c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Blood component transfusion; Fresh frozen plasma; Pulmonary edema; Warfarin

Indexed keywords

FRESH FROZEN PLASMA; INFUSION FLUID; VITAMIN K GROUP; WARFARIN; ANTICOAGULANT AGENT;

ADULT; AGED; ARTICLE; BLOOD TRANSFUSION REACTION; FEMALE; HUMAN; INCIDENCE; LUNG EDEMA; LUNG INJURY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRANSFUSION ASSOCIATED CIRCULATORY OVERLOAD; TRANSFUSION RELATED ACUTE LUNG INJURY; TREATMENT OUTCOME; TREATMENT RESPONSE; ACUTE LUNG INJURY; ADVERSE EFFECTS; BLOOD CLOTTING; BLOOD COMPONENT THERAPY; CHEMICALLY INDUCED; DRUG EFFECTS; HEMORRHAGE; HOSPITAL EMERGENCY SERVICE; INTERNATIONAL NORMALIZED RATIO; MASSACHUSETTS; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PLASMA; STATISTICAL MODEL; TERTIARY CARE CENTER; TIME FACTOR; VERY ELDERLY;

ACUTE LUNG INJURY; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD COMPONENT TRANSFUSION; BOSTON; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEMORRHAGE; HUMANS; INCIDENCE; INTERNATIONAL NORMALIZED RATIO; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PLASMA; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TERTIARY CARE CENTERS; TIME FACTORS; WARFARIN;

EID: 84958280987     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13212     Document Type: Article

References (34)

1. Dzik WS. Reversal of drug-induced anticoagulation: old solutions and new problems. Transfusion 2012; 52(Suppl. 1): 45S-55S.
2. Hirsh J, Fuster V, Ansell J, Halperin JL, American Heart Association; American College of Cardiology Foundation. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003; 107: 1692-711.
3. Funk DM. Coagulation assays and anticoagulant monitoring. Hematology Am Soc Hematol Educ Program 2012; 2012: 460-5.
4. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Arch Intern Med 2007; 167: 1414-19.
5. Fang MC, Go AS, Hylek EM, Chang Y, Henault LE, Jensvold NG, Singer DE. Age and the risk of warfarin-associated hemorrhage: the anticoagulation and risk factors in atrial fibrillation study. J Am Geriatr Soc 2006; 54: 1231-6.
6. Oden A, Fahlen M. Oral anticoagulation and risk of death: a medical record linkage study. BMJ 2002; 325: 1073-5.
7. Limdi NA, Beasley TM, Baird MF, Goldstein JA, McGwin G, Arnett DK, Acton RT, Allon M. Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 2009; 20: 912-21.
8. Levine MN, Raskob G, Landenfeld S, Kearon C. Hemorrhagic complications of anticoagulant treatment. Chest 2001; 119(1 Suppl.): 108S-21S.
9. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 21: 2002-12.
10. Zareh M, Davis A, Henderson S. Reversal of warfarin-induced hemorrhage in the emergency department. West J Emerg Med 2011; 12: 386-92.
11. Freedman MD. Oral anticoagulants: pharmacodynamics, clinical indications and adverse effects. J Clin Pharmacol 1992; 32: 196-209.
12. Basu D, Kulkarni R. Overview of blood components and their preparation. Indian J Anaesth 2014; 58: 529-37.
13. Erber WN, Perry DJ. Plasma and plasma products in the treatment of massive haemorrhage. Best Pract Res Clin Haematol 2006; 19: 97-112.
14. Goldstein JN, Thomas SH, Frontiero V, Joseph A, Engel C, Snider R, Smith EE, Greenberg SM, Rosand J. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. Stroke 2006; 37: 151-5.
15. Toy P, Lowell C. TRALI - definition, mechanisms, incidence, and clinical relevance. Best Pract Res Clin Anaesthesiol 2007; 21: 183-93.
16. US Food and Drug Administration. Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2013: 2013 US Department of health and human services. Rockville, MD: US Food and Drug Administration, 2013.
17. Popovksy MA. Transfusion and the lung: circulatory overload and acute lung injury. Vox Sang 2004; 87(Suppl. 2): 62-5.
18. Wallis JP. Transfusion-related acute lung injury (TRALI) - under-diagnosed and under-reported. Br J Anaesth 2003; 90: 573-6.
19. Narick C, Triulzi DJ, Yazer MH. Transfusion-associated circulatory overload after plasma transfusion. Transfusion 2012; 52: 160-5.
20. Li G, Rachmale S, Kojicic M, Shahjehan K, Malinchoc M, Kor DJ, Gajic O. Incidence and transfusion risk factors for transfusion-associated circulatory overload among medical intensive care unit patients. Transfusion 2012; 51: 338-43.
21. Clifford L, Slingh A, Wilson GA, Toy P, Gajic O, Malinchoc M, Herasevich V, Pathak J, Kor DJ. Electronic health record surveillance algorithms facilitate the detection of transfusion-related pulmonary complications. Transfusion 2013; 53: 1205-16.
22. Sarode R, Milling TJ Jr, Refaii MA, Mangione A, Schneider A, Durn BL, Goldstein JN. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013; 128: 1234-43.
23. Goldstein JN, Refaii MA, Milling TJ Jr, Lewis B, Goldberg-Alberts R, Hug BA, Sarode R. Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomized trial. Lancet 2015; 385: 2077-87.
24. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) - a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42: 377-81.
25. Centers for Disease Control. National Healthcare Safety Network Biovigilance Component Hemovigilance Module Surveillance Protocol. http://www.cdc.gov/nhsn/PDFs/Biovigilance/BV-HV-protocol-current.pdf. Accessed 4 June 2015.
26. Skeate RC, Eastlund T. Distinguishing between transfusion related acute lung injury and transfusion associated circulatory overload. Curr Opin Hematol 2007; 14: 682-7.
27. Bux J, Sachs UJ. The pathogenesis of transfusion-related acute lung injury. Br J Haematol 2007; 136: 788-99.
28. Silliman CC. The two-event model of transfusion-related acute lung injury. Crit Care Med 2006; 34(5 Suppl.): S124-31.
29. Silliman CC, Fung YL, Ball JB, Khan SY. Transfusion-related acute lung injury (TRALI): current concepts and misconceptions. Blood Rev 2009; 23: 245-55.
30. Magee G, Zbrozek A. Fluid overload is associated with increases in length of stay and hospital costs: pooled analysis of data from more than 600 US hospitals. Clinicoecon Outcomes Res 2013; 5: 289-96.
31. Frumkin K. Rapid reversal of warfarin-associated hemorrhage in the emergency department by prothrombin complex concentrates. Ann Emerg Med 2013; 62: 616-26.
32. Lankiewicz MW, Hays J, Friedman KD, Tinkoff G, Blatt PM. Urgent reversal of warfarin with prothrombin complex concentrate. J Thromb Haemost 2006; 4: 967-70.
33. Steiner T, Rosand J, Diringer M. Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke 2006; 37: 256-62.
34. Segal JB, Dzik WH, Transfusion Medicine/Hemostasis Clinical Trials Network. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005; 45: 1413-25.